Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Metronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the LiteratureA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerNational consensus in China on diagnosis and treatment of patients with advanced breast cancerThe role of taxanes in triple-negative breast cancer: literature reviewSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesTheory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell KillWeekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice studyLong term responders to palliative chemotherapy for advanced biliary tract cancer.Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancerFirst-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients.Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer.Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Drug rechallenge and treatment beyond progression--implications for drug resistance.Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer.Advances in Breast Cancer - Looking Back over the Year.Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.Clinical pathology of metastatic gastric carcinoma to the breast: A report of two cases and a review of literature.Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.Complete and Sustained Response with a Doublet Chemotherapy Protocol in an 81-Year-Old Patient with Metastatic Breast Cancer.Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer.Metronomics as maintenance treatment in oncology: time for chemo-switch.Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.Evaluation of the seventh AJCC TNM staging system for gastric cancer: a meta-analysis of cohort studies.Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Eribulin long-term response and rechallenge: report of two clinical cases.Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.Ten-year survival in women with primary stage IV breast cancer.Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial.
P2860
Q26745420-611BD492-F568-46F8-A435-237D5D0A4BA2Q26745462-E4598A36-A883-4EA3-A990-6163054D33C6Q26752846-F708A443-6B5D-4049-A712-769AFEB8CF6EQ26775621-218E9AE3-70B8-404C-8ED7-05F57CC9F1D9Q26798356-CB87ED91-C83B-4CFC-9118-40C86AED8560Q28080469-C87369B8-7405-4723-99BB-E977C8114987Q28550211-9D78295C-E7CB-4767-BB03-C7AAF6745156Q33401069-F6DEB1E0-2689-4295-BA4E-8133F2EE7FE7Q33593193-37B7B758-8A89-43AB-BBB2-718E37B44FF1Q34130140-B2B688A9-80AB-4248-8A77-1E97B633F037Q34452707-CC923EC4-32FE-4082-8E96-32236593CD65Q34993796-4634AC96-D49A-44E1-890A-81A28BD5C03AQ35205290-E425EFF2-5059-4ACE-BC50-AE223AF5BE6BQ35507680-9C3A1D07-EE2E-47FC-BF0E-927D6271B927Q35633623-5A42E5B9-D119-410F-9949-9CE98A079EE1Q35691756-415DD970-0ABD-4868-96FC-40F3D3F1C4E3Q35815486-62452658-1329-44D4-96B4-3D5F48EDCD47Q35967416-424BF689-8833-474B-B16E-69657D9C25A8Q36085860-82CE5CC9-7910-4AAC-8E30-CF5BDC1AB17CQ36295107-F271D147-FF2E-4954-B379-76D195B76637Q36698501-992736E9-14ED-4756-B635-542E4DC6C434Q36779798-61A864FC-2A18-4CC7-BC75-5E4FD5E6C8BFQ36825778-897053BF-423D-45A5-96BC-4FB827550F11Q36836599-2F93ED6E-F266-48DB-AC68-7307E45C3F2AQ37236305-FEEA337D-F2F1-4CA0-A43E-F7FC4737D919Q37385672-128F1B2A-FAD3-4134-9C99-8178D62A184FQ37428290-5F9EDCC7-0970-4E6E-8A5B-EA8DF5CAA83FQ37604159-8AAFCD33-3FD7-4F3A-ACF7-002692F3E702Q37707573-8316CDE9-81F9-4AAA-B028-C54B94AC43B5Q37964713-5109C4F1-7ED6-4B31-88A0-F13C94223805Q38201682-86E7431D-A452-4B99-8D28-6427073313FFQ38245797-48E188B4-58A3-4992-BD91-D37F5C893A87Q38638654-91D4564F-5076-45E5-8025-4939FC7E07D1Q38686613-63B675A8-4A1B-4CDD-80D3-B9D37AC390F8Q38782118-F3C031A8-3F06-4D64-9DB6-68FDA3845180Q40581747-4F160501-C878-42FF-9784-580B77F3FB03Q41346534-C5D33883-F2FC-4C13-B9F8-CA566C3729EAQ41701535-8F57AF8E-245A-49C9-8C74-7638342DAC4DQ47628083-1BE7F763-F8E6-4E76-9067-482211036449Q47640247-A8DC8F3B-9F0B-4FE6-8985-CE8FAA3420C3
P2860
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Duration of chemotherapy for m ...... of randomized clinical trials.
@en
Duration of chemotherapy for m ...... of randomized clinical trials.
@nl
type
label
Duration of chemotherapy for m ...... of randomized clinical trials.
@en
Duration of chemotherapy for m ...... of randomized clinical trials.
@nl
prefLabel
Duration of chemotherapy for m ...... of randomized clinical trials.
@en
Duration of chemotherapy for m ...... of randomized clinical trials.
@nl
P2093
P50
P356
P1476
Duration of chemotherapy for m ...... of randomized clinical trials
@en
P2093
Andrea DeCensi
Dino Amadori
Mariapia Sormani
Martin Stockler
Mauro D'Amico
Nicholas Wilcken
P304
P356
10.1200/JCO.2010.31.5374
P407
P577
2011-04-04T00:00:00Z